The ELEVATE Study shows that atogepant effectively prevents episodic migraine.

Published Date: 24 Apr 2023

Atogepant (Qulipta) performed better than a placebo in the ELEVATE study for preventing episodic migraine in patients who were resistant to other treatments.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

New protein target discovered for childhood medulloblastomas

2.

Effects of Recombinant Replacement Therapy Explained in Detailed Regarding Genetic Clotting Disorder.

3.

Standardized criteria for amino acid PET imaging could improve diagnosis and treatment of brain metastases

4.

PFS in R/R Mantle Cell Lymphoma is Improved by Ibrutinib-Venetoclax.

5.

'Ray of hope': New developments in the fight against various cancers.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot